ammonium hydroxide and su 11248

ammonium hydroxide has been researched along with su 11248 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ativitavas, T; Kongsuphon, N; Konmun, J; Ngamphaiboon, N; Soukavanitch, M; Teeraaumpornpunt, N	1

Other Studies

1 other study(ies) available for ammonium hydroxide and su 11248

Article	Year
Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib. Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:3 Topics: Aged; Ammonia; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Indazoles; Middle Aged; Neurotoxicity Syndromes; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome; Withholding Treatment	2019

Article

Year

Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib.

Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:3

Topics: Aged; Ammonia; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Indazoles; Middle Aged; Neurotoxicity Syndromes; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome; Withholding Treatment

2019